ENTRADA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $142.3M | $125.3M | $99.9M |
| SG&A Expense | $41.1M | $38.5M | $32.3M |
| Operating Income | $-157.9M | $47.0M | $-3.2M |
| Operating Margin | -621.1% | 22.3% | -2.5% |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | $924.0K | $859.0K | $18.7M |
| Net Income | $-143.8M | $65.6M | $-6.7M |
| Net Margin | -565.5% | 31.1% | -5.2% |
| EPS (Basic) | $-3.47 | $1.76 | $-0.20 |
| EPS (Diluted) | $-3.47 | $1.68 | $-0.20 |
| Shares Outstanding (Basic) | 41.4M | 37.3M | 33.1M |
| Shares Outstanding (Diluted) | 41.4M | 39.0M | 33.1M |
| Dividends Per Share | — | — | — |